We assessed baseline knowledge of PCPs and diabetologists/endocrinologists (D/Es) and determine if an online continuing medical education (CME) could improve individualized treatment of patients with T2D. A 3-question knowledge and 1-question confidence linked pre-/post assessment study designed with McNemar’s chi-squared test (5% significance level P <.05) and Cramer’s V (<0.05 no effect; 0.06-0.15 small effect; 0.16-0.30 medium effect; >0.30 large effect) assessed educational effect. The activity launched December 19, 2017 and data collected through January 19, 2018. PCPs (N=585) demonstrated a lower baseline knowledge level compared to D/Es (N=118): • 29% of PCPs compared to 81% of D/Es correctly identified which basal insulin had a lower risk for hypoglycemia • 52% of PCPs compared to 75% of D/Es correctly identified the regimen needed to decrease the risk for hypoglycemia and maintain glucose control • 42% of PCPs compared to 62% of D/Es accurately distinguished between basal insulin and longer-acting basal insulin. Overall improvements were seen after participation in the CME activity for both PCPs (N=585, P<.0001, large effect V=0.343) and D/Es (N =118, P<.0001, medium effect V=0.290). • 48% of PCPS (P <.0001) and 15% of D/Es (P=.0008) improved related to risk of hypoglycemia with longer-acting basal insulin • 25% of PCPs (P<.0001) and 20% of D/Es (P=.0011) improved on selecting a regimen to minimize hypoglycemia risk • 40% of PCPs (P<.0001) and 35% of D/Es (P<.0001) improved related to differences in basal versus longer-acting basal insulin • 27% of PCPs and 15% of D/Es reported increased confidence in prescribing basal insulins for patients with T2D. This study demonstrates the success of CME online activity on improving clinical knowledge and confidence of PCPs and D/Es related to evidence-based use of basal insulin for T2D. PCPs especially would benefit from further education on differences between traditional and newer, longer-acting basal insulins.


A. Larkin: None. C.S. Healy: None. A. Le: None.


Novo Nordisk

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.